Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1401-1413

  Levi, Edi ^a,b   Zhang, Liyue ^a,c   Aboukameel, Amro ^b   Rishi, Sunny ^a   Mohammad, Ramzi M ^b   Polin, Lisa ^a,b   Hatfield, James S ^a   Rishi, Arun K ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

Apoptosis; CARP 1; Diffuse large B cell lymphoma; Xenografts

Indexed keywords

CASPASE 3; CASPASE 9; CELL CYCLE AND APOPTOSIS REGULATORY PROTEIN 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN KINASE B; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAJI CELL; SURVIVAL; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARRIER PROTEINS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSPLANTATION, HETEROLOGOUS;

EID: 79959618448     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1442-6     Document Type: Article

References (27)

1. Reed JC, Doctor KS, Godzik A (2004) The domains of apoptosis: a genomics perspective. Science's STKE, pp 1-29
2. Rishi AK, Zhang L, Boyanapalli M et al (2003) Identification and characterization of a Cell-cycle and apoptosis regulatory protein (CARP)-1 as a novel mediator of apoptosis signaling by Retinoid CD437. J Biol Chem 278:33422-33435 (Pubitemid 37055796)
3. Kim JH, Yang CK, Heo K et al (2008) CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes. Mol Cell 31:510-519
4. Ou C-Y, Kim JH, Yang CK, Stallcup MR (2009) Requirement of cell cycle and apoptosis regulator 1 for target gene activation by Wnt and β-Catenin and for anchorage-independent growth of human colon carcinoma cells. J Biol Chem 284:20629-20637
5. Rishi AK, Zhang L, Yu Y et al (2006) Cell cycle and apoptosis regulatory protein (CARP)-1 is involved in apoptosis signaling by epidermal growth factor receptor. J Biol Chem 281:13188-13198 (Pubitemid 43855230)
6. A clinical evaluation of the International Lymphoma Study group classification of non-Hodgkin's lymphoma (1997) The non-Hodgkin's lymphoma classification project. Blood 89:3909-3918
7. Shipp MA, Abeloff MD, Antman KH et al (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 17:423-429 (Pubitemid 29022421)
8. Alizadeh A, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 4051:503-511 (Pubitemid 30082188)
9. Shipp MA, Ross KN, Tamayo P (2002) et al. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74 (Pubitemid 34101731)
10. Wadia JS, Dowdy SF (2004) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57:579-596
11. Borghouts C, Kunz C, Groner B (2005) Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci 11:713-726 (Pubitemid 41684258)
12. Snyder EL, Meade BR, Saenz CC, Dowdy SF (2004) Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biology 2:186-193
13. Zhang L, Levi E, Majumder P et al (2007) Transactivator of transcription tagged cell cycle and apoptosis regulatory protein-1 peptides suppress growth of human breast cancer cells in vitro and in vivo. Mol Cancer Ther 6(5):1661-1672 (Pubitemid 46954033)
14. Mohammad RM, Mohamed AN, Smith MR et al (1993) A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet 70:62-67
15. Mohammad RM, Pettit GR, Almatchy VP et al (1998) Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. Anticancer Drugs 9:149-156 (Pubitemid 28080636)
16. Mohammad RM, Beck FW, Al-Katib AM (2000) Non-Hodgkins lymphoma cell lines. In: Cancer cell lines part II, Leukemias and Lymphomas, vol. 3. Kluwer Academic Publishers, Boston, pp 295-320
17. Smith MR, Jin F, Joshi I (2004) Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in SCID mouse/human lymphoma xenografts. Mol Cancer Ther 3:1693-1699 (Pubitemid 40136726)
18. Mohammad RM, Wall NR, Dutcher JA, Al-Katib A (2000) The addition of bryostatin 1 to CHOP chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 6:4950-4956 (Pubitemid 32110441)
19. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569-1572
20. Smith MR, Joshi I, Jin F, Obasaju C (2005) Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in SCID mice. BMC Cancer 5:103-111
21. Doroshow JH (2001) Anthracyclines and anthracenediones. In: Bruce A. Chabner, Dan L. Longo (eds) Cancer and chemotherapy: principles and practice (3rd edn), pp 500-537
22. Froesch BA, Aime-Sempe C, Leber B et al (1999) Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain. J Biol Chem 274:6469-6475 (Pubitemid 29111062)
23. Salven P, Teerenhovi L, Joensuu H (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90:3167-3172 (Pubitemid 27444212)
24. Moller MB, Kania PW, Ino Y et al (2000) Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia 14(5):898-904 (Pubitemid 30235069)
25. Blagoev B, Kratchmarova I, Ong S-E et al (2003) A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat Biotechnol 21:315-318 (Pubitemid 36314817)
26. Matsuoka S, Ballif BA, Smogorzewska A et al (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:1160-1166 (Pubitemid 46877472)
27. Beausoleil SA, Jedrychowski M, Schwartz D et al (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA 101:12130-12135 (Pubitemid 39145408)